Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2024-02-12 00:00:00 ET · period of report 2024-01-18 · accession 0001048477-24-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-12 | 2024-01-18 | BMRN | BIENAIME JEAN JACQUES | Dir | L - Small Acq | $92.60 | +40 | 419.6K | +0.0% | +$3,704 |
| DM | 2024-02-12 | 2024-02-08+ | BMRN | BIENAIME JEAN JACQUES | Dir | M - OptEx | $63.10 | +30.0K | 434.6K | +7% | +$1.89M |
| DM | 2024-02-12 | 2024-02-08+ | BMRN | BIENAIME JEAN JACQUES | Dir | S - Sale+OE | $89.03 | -30.0K | 419.6K | -7% | -$2.67M |
| DM | 2024-02-12 | 2024-02-08+ | BMRN | BIENAIME JEAN JACQUES | Dir | M - OptEx | $0.00 | -30.0K | 146.0K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-18 | L | A | 40 | $92.60 | 419,602 | D | — | — | (F1) The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 40 shares, with the reporting person's sale of shares at a price of $98.19 on January 9, 2024. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. (F2) The price in column 4 is the weighted average price. The purchase price actually paid ranged from $92.595 to $92.60. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 2 | Common | Common Stock | 2024-02-08 | M | A | 15,000 | $63.10 | 434,602 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. |
| 3 | Common | Common Stock | 2024-02-09 | M | A | 15,000 | $63.10 | 434,602 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. |
| 4 | Common | Common Stock | 2024-02-09 | S | D | 15,000 | $88.28 | 419,602 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. |
| 5 | Common | Common Stock | 2024-02-08 | S | D | 15,000 | $89.77 | 419,602 | D | — | — | (F3) Trade made pursuant to a 10b5-1 plan executed on August 7, 2023. |
| 6 | Derivative | Stock Option (Right to Buy Common Stock) | 2024-02-09 | M | D | 15,000 | $0.00 | 131,000 | D | $63.10 · 2014-12-04 to 2024-06-03 | 15,000 Common Stock | (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |
| 7 | Derivative | Stock Option (Right to Buy Common Stock) | 2024-02-08 | M | D | 15,000 | $0.00 | 146,000 | D | $63.10 · 2014-12-04 to 2024-06-03 | 15,000 Common Stock | (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |